FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332592258> ?p ?o ?g. }

• W2332592258 endingPage "49" @default.
• W2332592258 startingPage "48" @default.
• W2332592258 abstract "case reportPancytopenia related to Graves’ disease Mohammed Hegazi, Ramesh Kumar, Zouheir Bitar, and Eman Ibrahim Mohammed Hegazi Department of Medicine, Al Adan Hospital, Riqah, Ahmadi, Kuwait Search for more papers by this author , Ramesh Kumar Department of Medicine, Al Adan Hospital, Riqah, Ahmadi, Kuwait Search for more papers by this author , Zouheir Bitar Department of Medicine, Al Adan Hospital, Riqah, Ahmadi, Kuwait Search for more papers by this author , and Eman Ibrahim Department of Hematology, Al Adan Hospital, Riqah, Ahmadi, Kuwait Search for more papers by this author Published Online:7 Feb 2008https://doi.org/10.5144/0256-4947.2008.48SectionsPDF ToolsAdd to favoritesDownload citationTrack citations ShareShare onFacebookTwitterLinked InRedditEmail AboutIntroductionPancytopenia is a serious hematological disorder that, apart from primary marrow failure, may be secondary to several other conditions. These include infection, radiation, drugs (especially cytotoxic drugs), and certain metabolic diseases.1 Among the latter, the association between hyperthyroidism and pancytopenia is reported least commonly.2 The pathogenesis of such an association is not clearly understood, though hypotheses of immunogenic and toxic mechanisms have been advocated.3 The response of pancytopenia to treatment of hyperthyroidism confirms the casual relationship and may preclude any other treatment modalities of pancytopenia.CASEA 43-year-old female presented with dizziness, dyspnea, and bilateral lower limb edema. Clinical examination showed marked pallor and signs of congestive heart failure. There was no lymphadenopathy or hepatosplenomegaly. Biochemical investigations, except for raised hepatic enzymes (AST=233 IU/L, ALT=80 IU/L), which were attributed to hepatic congestion, essentially showed normal findings. Hematological parameters before treatment are shown in Table 1. A blood smear showed a microcytic hypochromic picture with no polychromasia or normoblasts. The reticulocyte count was 2%, serum iron was 34.3 μmol/L, serum transferrin was 1.5 g/L, serum ferritin was 43 ng/mL, serum vitamin B12 was 378 pg/mL (normal, 148–443 pmol/L), and serum folate was 6.2 ng/mL (normal, >2 ng/mL). Hematologically, pancytopenia because of a microcytic hypochromic picture with an increased iron status was puzzling. Paroxysmal nocturnal hemoglobinuria (PNH) was suspected, but could not be supported by specific testing. Bone marrow examination, including trephine biopsy was performed. It showed a hypercelluar marrow with normoblastic hyperplasia, normal granulopoiesis and normal megakaryopoiesis. With these findings, pancytopenia was considered either immune-based or related to a bone marrow stem cell disorder like myelodysplastic syndrome, though no suggestive morphological findings could be observed. A direct antiglobulin test and auto-immune profile (ANA, anti-DNA, C3, and C4) were normal.Table 1 Hematological findings before and after treatment of Graves’ disease with carbimazole.Before carbimazole therapyAfter recovery from hyperthyroidismHemoglobin (gm/L) (112–157 gm/L)73.00121.00White blood cell (WBC) count (×109/L) (3.9–10×109/L)3.205.40Platelets (×109/L) (182–369×109/L)55199.00Mean corpuscular volume (MCV) (fL) (74.9–94.8 fL)62.1080.00Mean corpuscular hemoglobin (MCH) (pg) (25.6–32.2)19.9026.00Thyroid stimulating hormone (TSH) (μIU/ml) (0.27–4.2μIU/ml)0.011.15T4 (thyroxine) (pmol/L) (7–21 pmol/L)64.805.17While hematological aspects were being debated, the results of thyroid function tests were received and showed a markedly reduced TSH (0.01 μIU/mL) with a raised free T4 64.8 pmol/L (normal range), a surprising finding indicating marked hyperthyroidism. Retrospective clinical examination showed mild bilateral exophthalmos and a mild diffuse thyroid prominence with a significant bruit over the thyroid gland. Unfortunately, these findings had been missed in the earlier clinical examination. The diagnosis of Graves’ disease was confirmed by thyroid scan and iodine I 131 uptake studies showing diffusely increased activity. Congestive cardiac failure was considered to be related to both anemia and hyperthyroidism. For Graves’ disease, treatment with carbimazol (30 mg/day) was started, and hematological management was given in the form of blood transfusion for anemia and antibiotic cover for neutropenia. No specific hematinic therapy was given. With resolution of the thyrotoxic state and a return to euthyroid status, the hematological parameters (Table 1) improved simultaneously and soon returned to normal.DISCUSSIONAn association of pancytopenia with hyperthyroidism is of rare occurrence. Only 7 case reports have been recorded in the literature.2–8 All, except one case that showed toxic adenoma,3 had Graves’ disease. The fact that pancytopenia resolved with reversal of hyperthyroidism in all the reported cases including our case provides ample testimony to the causal relationship between the two conditions. In all, except one case of aplasia, reported by Das et al,4 the bone marrow was hypercellular. Hematologically, pancytopenia in the presence of a hypercellular marrow could be related to either of the three mechanisms, either organ sequestration such as observed in hypersplenism, an enhanced removal of peripheral circulating blood cells by an immune or toxic mechanism, or hemopoietic stem cell dysfunction such as myelodysplasia. One or both of the latter two mechanisms could be responsible for pancytopenia related to hyperthyroidism. Whatever the mechanism of pathogenesis, it is recommendable that all cases of pancytopenia should be evaluated for hyperthyroidism even though it may not be clinically obvious in the first instance. Conversely, the CBC findings in patients with hyperthyroidism should be closely checked for pancytopenia, and if indicated, bone marrow examination should be considered before starting anti-thyroid therapy. Also, in such cases, it is not necessary to institute specific therapy for pancytopenia immediately. Initially, the treatment may only be supportive.Pancytopenia related to hyperthyroidism is much less commonly reported than single lineage abnormalities.2 Iguchi et al reported a case of pancytopenia due to Graves’ disease with recovery on methimazole therapy, though neutropenia showed a prolonged persistence due to a drug side effect.5 Duquenne et al published a report, including 3 cases of pancytopenia with hyperthyroidism, 2 with Graves’ disease and one with toxic adenoma; all hematological disorders disappeared when patients became euthyroid.3 Soeki et al reported a case of primary hyperthyroidism with pancytopenia that recovered after methimazole therapy, but later needed a subtotal thyroidectomy to control hyperthyroidism.6 Shaw et al reported a case of postbone marrow transplant pancytopenia that was found to be related to hyperthyroidism; the patient recovered on antithyroid therapy.2 Das et al reported a case of remission of aplastic anemia induced by treatment of Graves’ disease in a pediatric patient.4 Kebapcilar et al reported a case of recovery from pancytopenia and liver dysfunction after administration of propylthiouracil for Graves’ disease.7 Lima et al reported 4 patients with Graves’ disease who presented with pancytopenia at diagnosis, three of whom recovered on antithyroid drug therapy.8Pancytopenia is a recognized complication of hyperthyroidism. Though the mechanism is still unclear, recovery from hyperthyroidism is associated with a simultaneous reversal of pancytopenia. It is recommendable that evaluation of the patient’s thyroid status should be included among the investigations for pancytopenia, even though hyperthyroidism may not be clinically evident at the first instance. Conversely, hematological abnormalities in patients with hyperthyroidism should be carefully analyzed in view of the reported association between the two conditions. Specific treatment for pancytopenia in such cases should be deferred until the effect of anti-thyroid treatment is observable.ARTICLE REFERENCES:1. Young Neal S. Differential diagnosis of pancytopenia (table 94–1) . Harrison’s Principles of Int Med, 16th ed. 2005; Chapter 94:617. Google Scholar2. Shaw B, Mehta AB. Pancytopenia responding to treatment of hyperthyroidism: a clinical case& review of literature . Clinical & Laboratory Haematology. 2002; 246:385-387. Google Scholar3. Duquenne M, Lakomsky D, Humbert JC, Hadjadi S, Weryha G, Leclere J. Pancytopenie resolutive par le traitment d’une hyperthyroidie . La Presse Medicale. 1995; 24(17):807-810. Google Scholar4. Das PD, Wherrett D, Dror Y. Remission of aplastic anemia induced by treatment of Graves’ disease in a pediatric patient . Pediatr Blood Cancer. 2006Feb2[Epub ahead of print] pmid: 16456859. Google Scholar5. Iguchi H, Nakano M. Case of hyperthyroidism with pancytopenia . Nippon Naibunpi Gakkai Zasshi. 1983Aug20 59(8):1117-1122. Google Scholar6. Soeki T, Tamura Y, Kondo N, Shinohara H, Tanaka H, Bando K, Fukuda N. A Case of thyrotoxicosis with pancytopenia . Endocr J. 2001Jun 48(3):385-389. Google Scholar7. Kebapcilar L, Yesil S, Bayraktar F, Suklamaz A, Demir T, Gungor O, Alacacioglu I, Comlekci A. Recovery from pancytopenia and liver dysfunction after administration of propylthiouracil in Graves’ disease . Journal of the New Zealand Medical Association. 2005Aug12 118(1220):U1615. Google Scholar8. Lima CSP, Wittmann DEZ, Castro V, Tambascia MA, Lorand-Metze I, Saad STO, Costa FF. Pancytopenia in untreated patients with Graves’ disease . Thyroid. 2006Apr 16(4):403-409. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Volume 28, Issue 1January-February 2008 Metrics History Accepted1 April 2007Published online7 February 2008 InformationCopyright © 2008, Annals of Saudi MedicineThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License." @default.
• W2332592258 created "2016-06-24" @default.
• W2332592258 creator A5009552801 @default.
• W2332592258 creator A5034334879 @default.
• W2332592258 creator A5063644385 @default.
• W2332592258 creator A5083383996 @default.
• W2332592258 date "2008-01-01" @default.
• W2332592258 modified "2023-09-26" @default.
• W2332592258 title "Pancytopenia related to Graves’ disease" @default.
• W2332592258 cites W1983538859 @default.
• W2332592258 cites W1992997213 @default.
• W2332592258 cites W2136048531 @default.
• W2332592258 doi "https://doi.org/10.5144/0256-4947.2008.48" @default.
• W2332592258 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6074226" @default.
• W2332592258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18299644" @default.
• W2332592258 hasPublicationYear "2008" @default.
• W2332592258 type Work @default.
• W2332592258 sameAs 2332592258 @default.
• W2332592258 citedByCount "6" @default.
• W2332592258 countsByYear W23325922582012 @default.
• W2332592258 countsByYear W23325922582015 @default.
• W2332592258 countsByYear W23325922582016 @default.
• W2332592258 countsByYear W23325922582018 @default.
• W2332592258 countsByYear W23325922582020 @default.
• W2332592258 crossrefType "journal-article" @default.
• W2332592258 hasAuthorship W2332592258A5009552801 @default.
• W2332592258 hasAuthorship W2332592258A5034334879 @default.
• W2332592258 hasAuthorship W2332592258A5063644385 @default.
• W2332592258 hasAuthorship W2332592258A5083383996 @default.
• W2332592258 hasBestOaLocation W23325922581 @default.
• W2332592258 hasConcept C126322002 @default.
• W2332592258 hasConcept C187212893 @default.
• W2332592258 hasConcept C2776652619 @default.
• W2332592258 hasConcept C2779134260 @default.
• W2332592258 hasConcept C2779382419 @default.
• W2332592258 hasConcept C2780007613 @default.
• W2332592258 hasConcept C71924100 @default.
• W2332592258 hasConceptScore W2332592258C126322002 @default.
• W2332592258 hasConceptScore W2332592258C187212893 @default.
• W2332592258 hasConceptScore W2332592258C2776652619 @default.
• W2332592258 hasConceptScore W2332592258C2779134260 @default.
• W2332592258 hasConceptScore W2332592258C2779382419 @default.
• W2332592258 hasConceptScore W2332592258C2780007613 @default.
• W2332592258 hasConceptScore W2332592258C71924100 @default.
• W2332592258 hasIssue "1" @default.
• W2332592258 hasLocation W23325922581 @default.
• W2332592258 hasLocation W23325922582 @default.
• W2332592258 hasLocation W23325922583 @default.
• W2332592258 hasOpenAccess W2332592258 @default.
• W2332592258 hasPrimaryLocation W23325922581 @default.
• W2332592258 hasRelatedWork W1943470799 @default.
• W2332592258 hasRelatedWork W2026000561 @default.
• W2332592258 hasRelatedWork W2061563424 @default.
• W2332592258 hasRelatedWork W2070501940 @default.
• W2332592258 hasRelatedWork W2409151694 @default.
• W2332592258 hasRelatedWork W2412729395 @default.
• W2332592258 hasRelatedWork W2422476675 @default.
• W2332592258 hasRelatedWork W2556658508 @default.
• W2332592258 hasRelatedWork W2765379856 @default.
• W2332592258 hasRelatedWork W2994334483 @default.
• W2332592258 hasVolume "28" @default.
• W2332592258 isParatext "false" @default.
• W2332592258 isRetracted "false" @default.
• W2332592258 magId "2332592258" @default.
• W2332592258 workType "article" @default.